ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / INDV / insiders
LEGN (60) EWTX (41) LQDA (36) ARQT (54) ⌘ Pro Terminal β†’

Indivior Pharmaceuticals Inc. (INDV) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$35.37 +0.34% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $35.32

Indivior Pharmaceuticals Inc. (INDV) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D β€’ SELL / AVOID Cap $4.17B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INDV Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is INDV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Indivior Pharmaceuticals Inc. (NASDAQ: INDV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $35.37 (+0.34% 1D, market cap $4.17B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, INDV ranks #251 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does INDV compare to LEGN and EWTX in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INDV carries a Roarable D (51/100 RQD), trailing P/E of 19.8x, gross margin of 80.2%, and ROIC of 62.2%. By comparison, LEGN (Legend Biotech Corporation) holds a C- grade (60/100 RQD, P/E 32.8x, ROIC 9.9%, cap $4.21B) and EWTX (Edgewise Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -31.9%, cap $4.22B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INDV?
β–Ό

Per INDV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001625297), Indivior Pharmaceuticals Inc. generated $1.24B in revenue (+4.3% YoY), $210.0M in net income, and -$93.0M in free cash flow against $1.20B in total assets and $290.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $35.32 (-0.13%)🧬 Disciplined Float (+0.80% YoY Shares)βš™οΈ Cash Engine: 11/20 (D+) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY β€’ 49.7% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D Β· Rk D+
Cash (11)Whales (10)SEC (14)Macro (7)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-3.1% Base Target
$45 Bull$34 Base$27 Bear
πŸ“¬ FREE INDV RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for INDV)Realized 20D OHLCV Swing Band: Β±7.3%
Deterministic 5-Pillar Attribution (51/100 Composite)
πŸ” WHY INDV SCORES 51/100 (D) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (27% of score)

Altman Z-Score 3.13 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 5/9

β–² #2 Bullish Driver: Cash Engine Quality+11/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 80.2% Gross Margin

β–Ό #1 Drag / Risk Factor: Macro Regime Fit7/20 pts (-13 pt drag)

Macro rate sensitivity & RSI-14 (52.3) create a -13 pt regime headwind

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
43
Grade D$34.16+1.8% Next Q
Q2 (-2Q)
46
Grade D$34.79-0.1% Next Q
Q3 (-1Q)
48
Grade D$34.77+1.7% Next Q
Current
51
Grade D$35.37-1.3% Hist 90D Ξ±
Trajectory: D (43) β†’ D (51)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a INDV Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While INDV currently carries a cautious 51/100 (D) rating due to Macro Regime Fit (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($35.13) and Max Pain ($37.14) forces dealer call-delta covering toward $44.95.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.80% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INDVβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œINDV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

INDV Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (INDV)

No recent open-market Form 4 cluster sales or emergency dumps flagged on INDV. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INDV)

  • βœ“Walkthrough of INDV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
INDV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.26%πŸ“ HORIZONTAL RANGE
2026-11-03O $35.25H $35.37L $35.25C $35.37VOL 4.61M
RES: $36.71SUP: $32.30SMA50: $35.13SMA200: $35.70
$43.75$39.86$35.98$32.09$28.20RES $36.71SUP $32.30$35.372026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INDV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ INDV Butterfly Map β†’ + Track INDV β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
13.3%/yr Implied 5Y Growth

vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INDV today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for INDV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INDV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INDV)

Health Care Rank #251 of 1015 βš”οΈ LEGN vs INDV Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (INDV vs. LEGN, EWTX, LQDA, ARQT)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Indivior Pharmaceuticals Inc. (INDV) ranks #251 by composite RQD confidence (51/100, grade D) and #175 by equity capitalization ($4.17B). Within this direct 5-issuer industry benchmark cohort, INDV leads on earnings valuation at 19.8x trailing P/E, while INDV leads on capital efficiency and profitability with 62.2% ROIC and 80.2% gross margin. LEGN currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with INDV at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INDV ACTIVE
Indivior Pharmaceuticals Inc.
D 51/100 19.8x 80.2% 62.2% +0.34% $4.17B Benchmark Subject
LEGN
Legend Biotech Corporation
C- 60/100 32.8x β€” 9.9% -2.45% $4.21B /legn-vs-indv β†’
EWTX
Edgewise Therapeutics Inc.
D- 41/100 β€” β€” -31.9% -2.03% $4.22B /ewtx-vs-indv β†’
LQDA
Liquidia Corporation
D- 36/100 β€” β€” -12.6% -7.12% $4.03B /lqda-vs-indv β†’
ARQT
Arcutis Biotherapeutics Inc.
D+ 54/100 β€” 90.2% -3.0% -2.53% $4.03B /arqt-vs-indv β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001625297 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Indivior Pharmaceuticals Inc. (INDV) reported GAAP revenue of $1.24B (+4.3% vs. FY2024 revenue of $1.19B , and +13.4% cumulative change since FY2023) , GAAP net income of $210.0M, operating cash flow of -$27.0M, and free cash flow of -$93.0M (-1428.6% YoY). On the balance sheet, INDV closed FY2025 with $1.20B in total assets against $290.0M in total debt (Altman Z-Score: 3.13, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.24B $210.0M -$27.0M -$93.0M $1.20B $290.0M
FY2024 (FY) 2024-12-31 $1.19B $7.0M $36.0M $7.0M $1.32B $315.0M
FY2023 (FY) 2023-12-31 $1.09B -$126.0M -$300.0M -$349.2M $2.29B $535.5M

3. INDV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INDV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Indivior Pharmaceuticals Inc. (NASDAQ: INDV) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $35.37 (+0.34% 1D, market cap $4.17B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, INDV ranks #251 in composite RQD confidence.

How does INDV compare to LEGN and EWTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INDV carries a Roarable D (51/100 RQD), trailing P/E of 19.8x, gross margin of 80.2%, and ROIC of 62.2%. By comparison, LEGN (Legend Biotech Corporation) holds a C- grade (60/100 RQD, P/E 32.8x, ROIC 9.9%, cap $4.21B) and EWTX (Edgewise Therapeutics Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -31.9%, cap $4.22B). Among the 5-stock peer group, INDV leads on earnings multiple (19.8x) while INDV leads on capital efficiency (62.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INDV?

Per INDV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001625297), Indivior Pharmaceuticals Inc. generated $1.24B in revenue (+4.3% YoY), $210.0M in net income, and -$93.0M in free cash flow against $1.20B in total assets and $290.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INDV trading relative to its 50-day, 200-day, and 52-week technical levels?

INDV last traded at $35.37 (+0.34% on volume of 4,607,423 shares), positioning the stock +0.68% above its 50-day simple moving average ($35.13) and -0.92% below its 200-day simple moving average ($35.70). Across its 52-week range of $27.68 to $42.81, INDV sits at the 50.8% percentile with a 14-day RSI of 52.3 (NEUTRAL RANGE) and an implied next-earnings move of Β±7.3% ($32.79 to $37.95).

Direct Sub-Reports: INDV RQD Cockpit INDV 12M Forecast INDV Earnings & Move INDV Dividends & DRIP INDV Insiders & 13F INDV Whale Options INDV Profit Sankey INDV News & Why
ROARABLE RATING BRIEF β€’ RQD 51/100 (D) βœ“ SEC XBRL & RQD VERIFIED

INDV β€” Indivior Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Indivior Pharmaceuticals Inc. (INDV) earns a live Roarable RQD composite score of 51/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $35.37 (+0.34% 1D, market capitalization $4.17B).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 62.2%, gross margin of 80.2%, operating margin of 21.1%, and free cash flow yield of -2.24%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (14/20): Incorporates a 1.15x equity beta, Altman Z-Score of 3.13, Piotroski F-Score of 5/9, and Debt/Equity of 0.85x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Indivior Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Indivior Pharmaceuticals Inc. (INDV) reported $1.24B in annual revenue (up from $1.19B in FY2024, +4.3% YoY) and $210.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.09B revenue, -$126.0M net income) through FY2025, INDV scaled operating cash flow to -$27.0M and free cash flow to -$93.0M, backed by $1.20B in total assets against $290.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (D β€’ RQD 51/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -2.24% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $27.68 – $42.81 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 19.8x trailing P/E and 13.4x EV/EBITDA against 21.1% operating margins and a 1.15x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

β€” The Butterfly Supply-Chain Graph lists supply_chain as NONE with empty butterfly links and proprietary signals, so upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the provided sources.

  • Key Question #1: Can INDV sustain or expand its 21.1% operating margin and 62.2% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.24B and free cash flow of -$93.0M, how will capital allocation balance growth reinvestment against $290.0M in total debt?
  • Key Question #3: How sensitive is INDV's 18.4x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.15x)?

INDV Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Indivior Pharmaceuticals Inc. (INDV) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to INDV Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INDV Bull vs. Bear Conversation Board β€” What's Your Call at $35.37?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INDV 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INDV:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER β€’ FCF Compounder Hunter πŸ‚ BULLISH 🎯 Target: $42.44 (+20.0%)
πŸ“Œ Pinned Debate

Reported ROIC of 62.2% and FY 2025 net income of $210.0M, up from $7.0M in FY 2024, show earnings power that could support a re-rating

Long INDV at $35.37 targeting $42.44. Reported ROIC of 62.2% and FY 2025 net income of $210.0M, up from $7.0M in FY 2024, show earnings power that could support a re-rating if cash flow follows.. Institutional whale score is 10/20 and the risk/reward vs. the $27.68 52-week low is skewed heavily in favor of bulls.

CapAlloc_Nerd πŸ‚ BULL

@CashFlowKing Agree on the RQD 51/100 quality, though with 1.15 beta I'm scaling in with half-size at $35.37 and keeping dry powder in case we test $32.89.

SK SkepticalCFA RQD DEBATE OPENER β€’ Fundamental Contrarian 🐻 BEARISH 🎯 Target: $26.53 (-25.0%)
Spot @ $35.37

Free cash flow was -$93.0M in FY 2025 and the FCF yield is -2.24%, so reported profits are not yet converting to cash for shareholders.

I respect the product at Indivior Pharmaceuticals Inc., but the stock at $35.37 is a different story. Free cash flow was -$93.0M in FY 2025 and the FCF yield is -2.24%, so reported profits are not yet converting to cash for shareholders.. FCF yield is -2.24% and RQD sits at 51/100 (D) β€” why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%